Loading
Inflammatory Bowel Diseases / Fecal Microbiota Transplantation / Biological Therapy · Journal article
Gut Microbes · August 15, 2026
A consensus or society position rather than new primary data.
This is a narrative review of synthetic microbial communities (SynComs) as defined, rationally designed alternatives to fecal microbiota transplantation for modulating the gut microbiome in dysbiosis-related diseases. The review examines construction strategies, mechanisms of action, disease applications (C. difficile infection, inflammatory bowel disease, colorectal cancer), and translational barriers including manufacturing, biosafety, and regulation. It provides a conceptual framework rather than new empirical evidence or a systematic synthesis of clinical outcomes.
Narrative review. Patients with gut microbiome dysbiosis and associated intestinal diseases (C. difficile infection, inflammatory bowel disease, colorectal cancer).
SynComs are compositionally defined and rationally designed, distinguishing them from traditional donor-derived FMT preparations Mechanisms of action include direct targeted antagonism and modulation of the host immune network to restore intestinal homeostasis Current research landscape evaluated in three disease contexts: C. difficile infection, inflammatory bowel disease, and colorectal cancer
No primary efficacy or safety data reported; review does not synthesize or meta-analyse clinical trial outcomes Translational challenges identified include host colonization resistance, manufacturing, chemistry and control, biosafety risks, and regulatory framework gaps
Clinicians and researchers should understand SynComs as a distinct category of defined, rationally designed biotherapeutics that address safety and composition unknowns inherent to FMT. The review identifies that clinical translation faces significant regulatory, manufacturing, and biological barriers that remain incompletely resolved.
A narrative review synthesizing the state of knowledge on synthetic microbial communities as emerging biotherapeutics, establishing boundaries, mechanisms, and translational challenges without reporting primary experimental results.
As stated by the source record.
Clinicians and researchers should understand SynComs as a distinct category of defined, rationally designed biotherapeutics that address safety and composition unknowns inherent to FMT. The review identifies that clinical translation faces significant regulatory, manufacturing, and biological barriers that remain incompletely resolved.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gut microbiome dysbiosis causes various intestinal diseases. However, an undefined composition and potential biosafety risks limit the applicability of traditional fecal microbiota transplantation (FMT). Synthetic microbial communities (SynComs), which are compositionally defined and rationally designed emerging live biotherapeutics, offer a novel alternative to FMT. This review establishes strict boundaries between SynComs and traditional donor-derived preparations, comparatively evaluating "top-down" and "bottom-up" construction strategies. We explored the mechanisms underlying the SynComs-mediated synergistic restoration of intestinal homeostasis via direct targeted antagonism and modulation of the host immune network. Moreover, we systematically evaluated the current research landscape of SynComs in Clostridioides difficile infection, inflammatory bowel disease, and colorectal cancer. This review examines fundamental challenges, including host colonization resistance, chemistry, manufacturing, and control barriers, biosafety risks, and microbiokinetic regulatory frameworks, thereby addressing the translational gap. Our analysis of current literature provides a theoretical basis for the clinical translation of SynComs as emerging live biotherapeutics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.